electroCore (NASDAQ:ECOR) is scheduled to post its quarterly earnings results after the market closes on Monday, August 13th.

electroCore opened at $13.16 on Friday, according to Marketbeat Ratings. electroCore has a 52-week low of $12.85 and a 52-week high of $20.25.

In related news, major shareholder Global Health Innovation Merck acquired 166,666 shares of the business’s stock in a transaction dated Thursday, June 21st. The shares were purchased at an average price of $15.00 per share, for a total transaction of $2,499,990.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Several equities analysts have recently issued reports on the stock. JMP Securities assumed coverage on shares of electroCore in a report on Tuesday, July 17th. They set an “outperform” rating and a $23.00 price objective on the stock. BTIG Research assumed coverage on shares of electroCore in a report on Tuesday, July 17th. They set a “buy” rating and a $20.00 price objective on the stock.

electroCore Company Profile

electroCore, LLC, a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. It is developing gammaCore, a prescription-only vagus nerve stimulation therapy, for the acute treatment of pain associated with migraine and episodic cluster headache in adults.

Further Reading: Stock Symbol

Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.